Clinical Trial Update: An 8-Week Refractory Chronic Cough Study (MK-7264-021) [Phase 2]

View source ↗

Summary

Phase 2 trial update for an 8-week refractory chronic cough study (MK-7264-021) completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• MK-7264 (MK-7264)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Refractory Chronic Cough | Phase 2 | Status: COMPLETED | Results posted: 2019-11-25